BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37580402)

  • 1. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
    Ma P; Sun W
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8
    Braun M; Aguilera AR; Sundarrajan A; Corvino D; Stannard K; Krumeich S; Das I; Lima LG; Meza Guzman LG; Li K; Li R; Salim N; Jorge MV; Ham S; Kelly G; Vari F; Lepletier A; Raghavendra A; Pearson S; Madore J; Jacquelin S; Effern M; Quine B; Koufariotis LT; Casey M; Nakamura K; Seo EY; Hölzel M; Geyer M; Kristiansen G; Taheri T; Ahern E; Hughes BGM; Wilmott JS; Long GV; Scolyer RA; Batstone MD; Landsberg J; Dietrich D; Pop OT; Flatz L; Dougall WC; Veillette A; Nicholson SE; Möller A; Johnston RJ; Martinet L; Smyth MJ; Bald T
    Immunity; 2020 Oct; 53(4):805-823.e15. PubMed ID: 33053330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD226 identifies functional CD8
    Huang H; Huang Z; Ge J; Yang J; Chen J; Xu B; Wu S; Zheng X; Chen L; Zhang X; Jiang J
    Front Immunol; 2023; 14():1150803. PubMed ID: 37056782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
    Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
    Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8
    Viot J; Abdeljaoued S; Vienot A; Seffar E; Spehner L; Bouard A; Asgarov K; Pallandre JR; Renaude E; Klajer E; Molimard C; Monnien F; Bibeau F; Turco C; Heyd B; Peixoto P; Hervouet E; Loyon R; Doussot A; Borg C; Kroemer M
    Cell Mol Immunol; 2023 Apr; 20(4):365-378. PubMed ID: 36717657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD226
    Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
    Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
    Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
    Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
    Li J; Zhang H; Wu J; Li L; Xu B; Song Q
    Cancer Biomark; 2023; 38(1):77-102. PubMed ID: 37545222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6
    Li X; Gao Z; Chen J; Feng S; Luo X; Shi Y; Tang Z; Liu W; Zhang X; Huang A; Gao Q; Ke A; Zhou J; Fan J; Fu X; Ding Z
    Front Oncol; 2023; 13():1099385. PubMed ID: 37593098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating CD226
    Zhang Y; Zhao ZX; Gao JP; Huang YK; Huang H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4381-4389. PubMed ID: 36107244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
    Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
    Front Immunol; 2022; 13():998266. PubMed ID: 36248785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD226 opposes TIGIT to disrupt Tregs in melanoma.
    Fourcade J; Sun Z; Chauvin JM; Ka M; Davar D; Pagliano O; Wang H; Saada S; Menna C; Amin R; Sander C; Kirkwood JM; Korman AJ; Zarour HM
    JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
    Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the treatment-naive immune microenvironment in melanoma with
    Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers.
    Guillamón CF; Gimeno L; Server G; Martínez-Sánchez MV; Escudero JF; López-Cubillana P; Cabezas-Herrera J; Campillo JA; Abellan DJ; Martínez-García J; Martínez-Escribano J; Ferri B; López-Álvarez MR; Moreno-Alarcón C; Moya-Quiles MR; Muro M; Minguela A
    Eur Urol Oncol; 2021 Apr; 4(2):246-255. PubMed ID: 31411976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPRO-related CD8
    Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
    Front Immunol; 2022; 13():947841. PubMed ID: 36003382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.